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”Whether you believe you can do a thing or not, you are right” 
 
Henry Ford  
 
 
  
 ABSTRACT 
Background 
Several peptides derived from the gastrointestinal tract (GI) have been shown to have profound 
effects on GI motility, food intake and metabolism. Two such peptides, derived from the same 
prohormone, are the peptides ghrelin and obestatin, discovered in 1999 and 2005, respectively. 
The ghrelin receptor (GHS-R) is distributed in a large number of central and peripheral tissues, 
such as, the GI tract, pancreas, kidney, fat, skeletal muscle and several parts of the brain. The 
obestatin receptor still remains unknown. Two major molecular forms of ghrelin, acyl and des-
acyl ghrelin exist. They regulate GI motility peripherally in the local enteric nervous system, 
but also by activating hypothalamic peptides via the vagal nerve or the bloodstream by crossing 
the blood-brain barrier (BBB). Ghrelin is involved in a variety of metabolic functions by 
affecting the glucose homeostasis, fat metabolism, appetite and meal initiation. The role of 
obestatin and its interaction with ghrelin is still uncertain. 
Aims 
The main aims of this thesis were to investigate the role of obestatin and ghrelin in GI motility 
in vitro and in vivo in rodents and man.  
Material and methods 
Gastric emptying and small bowel motility were studied in vivo in rats with implanted gastric 
catheter and intestinal electrodes. Gastric emptying, oro-caecal transit, colonic transit and gut 
peptides were assessed in man. Ghrelin, obestatin or saline was infused in rats. Ghrelin or saline 
was infused in normal humans for 6 hours. In vitro studies with human GI tissue were also 
performed. Gastric emptying was studied in patients randomised to 3 hours saline or ghrelin 
infusion, before and day 2 after open colo-rectal surgery. Gastric emptying and changes in 
serum levels of GI peptide hormones were studied in obese subjects subjected to a liquid meal 
with acetaminophen before, 3 days, 2 months and 1 year after Roux-en-Y gastric bypass 
(RYGB) surgery.  
Results 
Whereas ghrelin stimulated GI motility, obestatin did not affect motility in vitro or in vivo in 
rats. Ghrelin increased gastric emptying in healthy humans and in patients after colo-rectal 
surgery. There was no effect on small bowel or colonic transit in healthy humans, but time to 
defecation was shorter when ghrelin was administered after colo-rectal surgery. Post-prandial 
elevations of glucose, insulin and GLP-1 occurred earlier and were higher with ghrelin in 
healthy humans. Plasma concentrations of ghrelin were unchanged after RYGB. Gastric 
(pouch) emptying was twice as fast after RYGB compared to before surgery. There was a 
progressive increase in several GI peptides after RYGB over 1 year after surgery.  
Conclusions 
In rodents ghrelin stimulates GI motility but obestatin has no effect. Ghrelin potently stimulates 
gastric emptying in healthy humans and in patients after surgery, while stimulation of intestinal 
motility seems more outspoken after surgery. In contrast to other studies plasma ghrelin was 
only significantly different on day 3 and thereafter not different after RYGB. Even if exogenous 
ghrelin can stimulate motility, endogenous ghrelin does not change after surgery and is less 
likely to modulate GI motility, transit or glucose metabolism after RYGB. However, early 
changes of other GI peptides (e.g. glucagon-like peptide-1) after RYGB likely contribute to the 
improved glucose homeostasis post surgery. 
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1 INTRODUCTION 
 
1.1 ANATOMY AND PHYSIOLOGY OF THE GASTROINTESTINAL 
 TRACT 
 
1.1.1 Stomach 
The stomach is anatomically divided into separate parts (cardia, fundus, corpus, antrum) and 
ends with the pyloric sphincter muscle before the duodenum. Circular and longitudinal 
muscles cooperate to grind and move the food into the duodenum. The rate of delivery of 
nutrients from the stomach to the duodenum is 1-4 kcal min-1 in healthy individuals. 
Depending on the caloric content and liquid or solid food content the gastric emptying rate 
will differ. The small intestine can influence the gastric emptying rate by a negative feedback 
mechanism. Peptide hormones secreted from the intestine (mainly the ileum), such as 
glucagon-like peptide-1 (GLP-1) and peptide YY (PYY) inhibit gastrointestinal (GI) motility 
and are involved in the so-called “ileal brake” mechanism, where signals from the lower GI 
tract inhibit the upper GI tract.  
 
The wall of the stomach contains four layers where the inner layer (mucosa) is protected by 
mucous produced from goblet cells. Other cells such as parietal cells secrete hydrochloric acid 
or intrinsic factor (for absorption of vitamin B12) and chief cells that secrete pepsinogen 
(precursor to pepsin that degrades proteins). Furthermore, there are enteroendocrine cells 
which secrete peptide hormones such as gastrin, ghrelin and obestatin. GI motility is 
controlled both by the local myenteric plexus (situated between the circular and longitudinal 
muscle layers), the vagal and sympathetic nerve system, as well as, by peptide hormones. 
 
1.1.2 Small bowel 
The small intestine is approximately 4 to 7 meters long, divided into the duodenum, jejunum 
and ileum and ends with the ileocecal valve, which prevents backflow from the colon. The 
layers of the small intestinal wall include the mucosa, submucosa, muscular layers and serosa. 
The main function of the small intestine is the absorption of nutrients, transport of chyme and 
indigestible materials to the colon. The small intestine is innervated by the vagus nerve and 
nerves from the spinal cord, as well as, the enteric nerve system (ENS). The enteric nervous 
system involves two separate collections of neurons located in the gut wall: 
¥ The myenteric plexus situated between the circular and the longitudinal muscle layers 
which mainly regulates the motility of the GI tract. 
¥ The submucosal plexus which regulates the blood flow of the intestinal wall and villus 
motility. 
 
There are two recognisable motility patterns in the small bowel; peristalsis and the migrating 
motor complex (MMC) [1]. Peristalsis is stimulated by mechanical and chemical stimuli and 
is mainly dependent on the ENS. The MMC consists of distinct phases with different defined 
patterns of contractility, propagation and regularity. The MMC cycle length varies between 
different species, but in fasting humans it recurs approximately every 90-120 minutes (from 
stomach to distal ileum) [2] and consists of 3 phases (in rodents it occurs about every 15 min 
(Fig 1): 
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I. A period of absence of contractile activity lasting 45-60 minutes.  
II. A period of 30 minutes charactericed by irregular contractile activity. 
III. Rapid peristaltic contractions lasting 5-15 minutes.  
 
Phase III is usually easy to recognise and is often measured in the proximal jejunum (Fig 1). 
Different phases of the MMC may occur in different parts of the small bowel and do not 
always reach the terminal ileum. If food is ingested, the motility pattern becomes irregular 
again. It has been proposed that this interdigestive peristalsis has a “housekeeping role” in 
cleaning the lumen of the bowel thereby preventing bacterial overgrowth. 
 
 
 
Fig 1. A representative recording of small bowel electrical activity in the rat (MMC) with 
defined phase IIIs (activity fronts). 
 
 
1.1.3 Colon and rectum 
The total length of the colon is about 1 meter and is divided into the cecum, ascending, 
transverse, descending and sigmoid colon. The rectum is usually defined as the last 15 cm 
proximal to the anal verge. The wall of the colon also includes an inner and outer smooth 
muscle layer with the myenteric nerve plexus situated in between. Movements of the colon 
are less frequent and the volume and consistency of the contents affect the rate of emptying 
[3].  
 
 
1.2 GASTROINTESTINAL PEPTIDE HORMONES  
 
1.2.1 Background 
Over 30 different peptide hormones are secreted from the GI tract and numerous of these 
regulate GI motility, as well as energy homeostasis. Some peptides are produced peripherally 
and others also centrally and are therefore sometimes referred to as members of the “gut-brain 
axis” [4]. A number of studies have proposed associations between GI peptides and diseases 
such as irritable bowel syndrome (IBS) [5, 6], obesity [4, 7, 8], anorexia nervosa [9], 
postoperative ileus (POI) [10] and diabetes [11].  
 
1.2.2 Ghrelin and its receptor 
Ghrelin is a 28-amino peptide derived from a larger peptide containing 117 amino acids [12] 
(Fig 2). The peptide was identified as a ligand for the growth hormone (GH) secretagogue 
receptor (GHS-R) and therefore found to stimulate GH from the pituitary gland. Further 
studies show that the peptide is mainly produced in the stomach, but also in most human 
tissues examined (brain, small intestine, adrenal gland, gonads, pancreas, kidney) [13, 14, 15]. 
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Ghrelin plasma levels are reduced up to 80% by gastrectomy [16]. The GHS-Rs are expressed 
throughout the GI tract [17], as well as, in the heart, lung, kidney, pancreas and adipose tissue. 
In the brain, GHS-Rs are found both in areas within and outside the blood-brain-barrier 
(BBB) including the hypothalamus, arcuate nucleus (ARC) [18], the nucleus of the solitary 
tract (NTS) and the dorsal motor nucleus of the vagus. A recent study found that brain areas 
involved in reward and motivation (amygdala, frontal cortex) were signalling when ghrelin 
was given intravenously to healthy volunteers during functional magnetic resonance imaging 
[19].  
 
 
 
Fig 2. Ghrelin and obestatin are derived from the 117-amino-acid peptide prepro-ghrelin. 
 
 
 
1.2.3 Structural variants of ghrelin 
Ghrelin circulates in acylated and des-acylated forms [12]. Both variants have recently found 
to be biologically active, but with different and even counteracting effects [20]. The ghrelin 
peptide is acylated by the enzyme GOAT (ghrelin O-acyl transferase) which is highly 
expressed in the stomach, pancreas and GI tract. The acylation is necessary for binding to the 
ghrelin receptor. Des-acylated ghrelin (which is found to be more than 2.5 higher in serum) 
exert its activity on a still unknown receptor. Studies in animals have shown that acylated 
ghrelin stimulates secretion of growth hormone (GH) from the pituitary [21], gastric motility 
and appetite resulting in increased bodyweight and consequently adiposity and increased 
insulin resistance. On the other hand des-acylated ghrelin counteracts the effect of acylated 
ghrelin and acts as a satiety signal by decreasing food intake and gastric emptying [22] [23]. 
This peptide also differs from acylated ghrelin by increasing the uptake of glucose and fatty 
acids in peripheral tissues, thus improving insulin sensitivity [24].  
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Fig 3. Some effects of acylated (AG) and des-acylated ghrelin in different organs. 
 
 
In vivo studies of rat gastro-duodenal motility have further shown that des-acyl ghrelin exerts 
inhibitory effects on gastric motility, but not on duodenal motility in the fasted state [25]. The 
communication between the periphery and brain seems to differ between the peptides as des-
acyl ghrelin does not activate the vagal pathway, but acts directly on receptors in the brain 
after crossing the BBB in contrast to acyl-ghrelin (Fig 3) [25]. 
 
1.2.4 Ghrelin and gastrointestinal motility 
GI motility is regulated by a complex network of peptide hormones and the nervous system. 
Historically, the most frequently studied GI hormones are CCK, secretin, gastrin and motilin. 
Other peptide hormones such as GLP-1, ghrelin, orexin, PYY and obestatin are receiving 
increasing attention. The ghrelin receptor was found to be structurally related to the motilin 
receptor [26] [27]. Both motilin and ghrelin stimulate gastric acid secretion [28] and emptying 
[29, 30]. In rat, the stimulatory effect of ghrelin on gastric emptying rate and small bowel 
motility has been extensively studied. Both resting muscle tension and nerve-mediated 
responses evoked by electric field stimulation (EFS) are increased by ghrelin [17, 31, 32]. In 
vivo, ghrelin induces MMC activity both in the rat [33, 34] and human. Some studies in 
rodents and humans have concluded that gastric motility is abolished by pharmacologically 
blocking the vagus nerve (atropine, capsaicin) or by surgical vagotomy. Others show 
contrasting results where ghrelin accelerates gastric emptying of a meal in vagotomised 
patients [35] and in diabetic gastroparesis [36]. 
 
Ghrelin acts both peripherally and centrally. Circulating peripheral ghrelin is released from 
the GI tract and studies in rodents have shown that the peptide reaches the brain by three 
mechanisms.  
 1. Directly via the bloodstream entering the brain where the BBB is lacking. 
 2. Directly by crossing the BBB [37].  
 3. Indirectly, via the vagus nerve.  
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Findings in rat experiments suggest that small amounts of ghrelin are also produced locally in 
the brain. In conclusion, peripherally as well as centrally produced ghrelin stimulates food 
intake in the regulatory parts of the brain where neurons that release neuropeptide Y (NPY) 
and AgRP (agouti protein related peptide) are activated. 
 
1.2.5 Ghrelin and energy homeostasis 
Ghrelin is secreted in a circadian pattern and plasma levels rise before meal-time [38] and fall 
postprandially usually within an hour. Interestingly, the levels rise as food is expected [38] 
whether or not the food is actually received [39] and a recently published study demonstrates 
that ghrelin levels even rise on visual presentation of a meal [40]. In rodents ghrelin acts as a 
meal initiator depending on the dark/light cycle [41]. It is not clear why ghrelin levels fall 
after a meal but the degree of reduction depends on the amount of ingested carbohydrates, 
proteins or fat [42] and it is necessary for the nutrients to reach the small bowel. Several 
studies demonstrate that both peripheral and central administration of ghrelin stimulates food-
intake in rodents [43] and humans [44]. Vagotomy inhibits the increase in food intake 
following high doses of exogenous ghrelin [45, 46, 47]. Total ghrelin is low in obese 
individuals [48] and consequently elevated in humans with low body mass index (BMI) [49, 
50, 51]. In summary, ghrelin regulates the body weight by modulating hunger and appetite, 
increasing GI motility and by signalling to different food regulatory areas in the brain.  
 
1.2.6 Role of ghrelin in glucose homeostasis 
It is well known that exogenously administered ghrelin increases glucose concentrations in 
plasma [24]. An increasing number of studies demonstrate that ghrelin suppresses insulin 
secretion [52]. Still the role of ghrelin in glucose homeostasis is not clear. Glucose 
homeostasis is a fine-tuned mechanism depending on both insulin secretion and insulin 
sensitivity, which reflects glucose uptake in liver, intestines, muscle and fat. There is also a 
complex regulation of glycogenolysis and gluconeogenesis in the liver and intestine. In 
addition, insulin secretion from islet β-cells in the pancreas is locally controlled by several 
different hormone producing cells; glucagon secreting α-cells, somatostatin producing δ-cells, 
pancreatic polypeptide (PP) secreting F-cells and ghrelin secreting P/D1-cells in humans and 
A-cells in rodents. More recently published data suggest that the major metabolic role of 
ghrelin is to maintain stable blood glucose levels in spite of low energy intake [38, 50, 53, 
54]. Animal studies have shown that ghrelin knock-out mice have improved glycemic control 
by enhanced insulin secretion [53], but are not able to maintain the same blood glucose levels 
compared to wild-type littermates during low calorie intake [55]. 
 
1.2.7 Obestatin 
Obestatin is derived from the same precursor gene as ghrelin (Fig 2). It was initially thought 
to bind to the orphan G protein coupled receptor GPR39. Early reports [56] proposed that the 
peptide had opposite effects of ghrelin and therefore inhibited food ingestion and GI motility. 
It was also described that the rate of gastric emptying in GPR39 knockout mice was faster 
[57]. Later studies including ours [58, 59, 60, 61] have questioned these findings and suggest 
that obestatin binds to a still undiscovered receptor and may have other functions than 
affecting GI motility. Studies of rodents have proposed that obestatin has several biological 
roles from promoting sleep and memory to involvement in fluid homeostasis [62, 63, 64, 65]. 
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1.2.8 Peptide YY and pancreatic polypeptide 
PYY and PP belong to the NPY family of peptides. PYY itself has two different forms, PYY 
1-36 and PYY 3-36. PYY 3-36 is the major form and cleaved from PYY 1-36 by the enzyme 
dipeptidyl peptidase-4 (DPP-4) in the circulation. PYY levels are low in the fasting state but 
rise after a meal and remain elevated for 1-2 hours depending on the amount of calories 
ingested [66]. Intake of fat stimulates PYY release more than proteins or carbohydrates. Both 
forms are secreted from the L-cells in the distal part of the GI tract with highest 
concentrations in colon and rectum (Fig 5). Low concentrations of PYY are also found in the 
brain. PYY and GLP-1 act as an “ileal brake” by inhibiting gastric emptying and secretion, 
gallbladder contraction and food intake [67, 68]. PYY also affects glucose homeostasis by 
increasing insulin-stimulated glucose uptake in peripheral tissues, and low levels of PYY are 
associated with elevated insulin resistance in humans [69]. 
 
PP is secreted from the pancreas (Fig 5), is released after food intake and inhibits gastric 
emptying [70]. It is also known to regulate glucose homeostasis by reducing the release of 
glucose as well as increasing the number of insulin receptors in the liver [71]. Both PP and 
PYY activate Y receptors (Y1- Y5) expressed in the liver, adrenal gland, intestines and brain. 
 
1.2.10 Somatostatin  
Somatostatin is a hormone located in most parts of the brain as well as in peripheral endocrine 
organs including pancreas, intestines, thyroid, kidneys and placenta. The hormone exists in 
two forms with 14 or 28 amino acids and is produced in the δ-cells of the intestine and the 
pancreas. The hormone acts as an inhibitor in most biological systems of the body and 
regulates GI motility and secretion, absorption of nutrients and smooth muscle tone in blood 
vessels as well as GI peptide hormone release. The release of several GI hormones including 
gastrin, cholecystokinin (CCK), insulin and glucagon are inhibited by somatostatin. Studies in 
healthy and obese subjects indicate that also ghrelin release is suppressed by somatostatin [72, 
73]. 
 
1.2.11 GLP-1, GLP-2 and glucagon 
The precursor peptide proglucagon is cleaved to organ specific peptides. Glicentin, consisting 
of 69 amino acids [74], is processed into glucagon and glicentin-related pancreatic 
polypeptide (GRPP) in the pancreatic α-cells. Another large molecule from the proglucagon 
is formed in the pancreas and named the major proglucagon fragment. A different process 
takes part in the brain or in the L-cells of the intestine where glicentin may be cleaved to 
GRPP and oxyntomodulin. The proglucagon fragment consists instead of two glucagon-like 
peptides (GLP-1 and GLP-2) and an intervening peptide (Fig 4). GLP-1 is even further 
processed in the L-cells resulting in GLP-1(7-37) and GLP-1(7-36)amide. GLP-1(7-37) 
usually exists in rats.  The L-cells are found both in the small intestine and colon but are 
mainly present in the ileum (Fig 5) [75]. The cells have microvilli protruding into the 
intestinal lumen and can thereby "analyse" the food content and regulate the peptide secretion. 
The mucosa of the intestine; however, also contain the enzyme DPP-4 which degrades GLP-1 
almost immediately. The peptide is further degraded in the liver and by enzymes lining the 
walls of blood vessels resulting in a half-life of GLP-1 in plasma of 1-2 minutes [76]. Apart 
from the intestines, GLP-1 is synthesized in neurons in the brainstem (NTS) and 
hypothalamus [77]. GLP-1 receptors are distributed in the kidney, pancreas, brain, heart and 
the GI tract [78]. 
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GLP-1 release is stimulated by luminal carbohydrates and lipids [79]. Increased blood sugar 
also stimulates the release of the hormone, which in turn slows gastric emptying and intestinal 
motility. The secretion is inhibited by somatostatin, independent of the vagal nerve. In 
contrast to these findings, the effect of GLP-1 on gastric motility seems to be driven by the 
vagus nerve [80]. The pancreas is another important target organ for GLP-1 as it inhibits 
glucagon secretion and stimulates the release of insulin. Interestingly, studies of rodents and 
human pancreatic tissue have shown that GLP-1 stimulates growth and survival of β-cells 
[81, 82]. GLP-1 analogues and DPP-4 inhibitors have been introduced as a treatment of 
diabetes type 2. The side effects are few and treatment with GLP-1 does not lead to 
hypoglycaemia. Other positive effects beside increased insulin secretion are reduced appetite 
and a moderate weight loss. GLP-2 is also produced in the L-cells of the GI tract but does not 
seem to regulate motility or insulin secretion. It acts more as a growth factor stimulating 
intestinal growth such as increased cell proliferation and blood flow [83]. Studies in rodents 
have shown that GLP-2 inhibits apoptosis of enterocytes and in colectomised patients villus 
height is increased resulting in better absorption capacity of the small bowel [84]. 
 
Glucagon is secreted from the pancreas (Fig 5) and glucagon receptors are expressed mainly 
in the liver and kidney, but also in the pancreas, brain, heart, eye and GI tract. Glucagon is 
extensively studied as a regulatory hormone of the glucose homeostasis preventing 
hypoglycaemia and counteracting the effects of insulin. To prevent low glucose levels, 
glucagon stimulates gluconeogenesis and glycogenolysis in the liver. The hormone has 
additional metabolic functions as it has been shown to lower food intake by decreasing meal 
size in humans [85] and further involvement in the lipid metabolism. 
 
 
 
Fig 4. Schematic presentation of the precursor peptide proglucagon processed to different 
peptides depending on organ.  
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1.2.12 Glucose-dependent insulinotropic polypeptide            
Glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 are recognised as incretins. 
Both are regarded as equally important but GIP is circulating at 10-fold higher 
concentrations in plasma. Both glucose and fat intake [79] stimulate GIP release from the 
K-cells in the duodenum and jejunum (Fig 5). GIP increases insulin secretion in humans in 
response to elevated glucose levels. A feedback mechanism exists as circulating insulin also 
affects the synthesis and secretion of GIP [86]. 
 
 
           Fig 5. The main sites of GI peptide hormone secretion 
 
 
 
1.3 LEPTIN  
 
Leptin is an adipokine mainly found in adipose tissue but also in the stomach, breast and 
gonads. Plasma leptin concentrations strongly correlate with BMI and are therefore increased 
in obese patients [87]. Although leptin levels are low during the fasting state and increase 
gradually after a meal [88] it is not clear if it is regulated by meals or by the amount of fat 
storage. When weight gain occurs, leptin levels rise and consequently suppresses production 
and secretion of neuropeptide Y [89] within the ARC. This in turn leads to reduced appetite 
and food intake.  
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2 AIMS 
The aim of this thesis was to investigate the role of ghrelin and obestatin in GI motility in 
vitro and in vivo in rodent and man. More specifically the aims were to investigate: 
 
 
¥ The role of obestatin in GI motility in vitro and in vivo in rat and the interaction of 
ghrelin and obestatin on GI motility. 
 
¥ The effect of ghrelin on oro-caecal and colon transit in healthy humans. 
 
¥ The effect of ghrelin on gastric emptying and post-operative ileus after colo-rectal 
surgery 
 
¥ The effect of Roux-en-Y gastric bypass (RYGB) surgery for obesity on plasma 
ghrelin concentrations, GI peptides and gastric (pouch) emptying. 
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3 MATERIAL AND STUDY SUBJECTS 
 
3.1 IN VITRO STUDIES OF RAT AND HUMAN TISSUE AND IN VIVO 
STUDIES OF RAT  
Adult male Sprague-Dawley rats (250-250 g) were used in study 1. They were kept under 
standardized conditions on a commercial diet. During study periods they were housed singly 
and recovered at least 1 week after surgery was performed. All efforts were made to minimize 
the number of animals used and culling was done by overdose of pentobarbitone or by CO2 
asphyxiation followed by cervical dislocation. 
 
3.2 SUBJECTS AND PATIENTS  
3.2.1 Study II 
Twelve men (age 26 ±1.2 years) participated in the study. The subjects were healthy and of 
normal weight (BMI 24.7 ±2.9 kg m-2). They had no medical history of GI disease or 
abdominal surgery (except for appendectomy more than 1 year ago) and stated bowel habits 
within normal range (not less than 3 bowel movements per week or more than 2 per day). No 
medications including antibiotics or laxatives were used during the whole study period. 
 
3.2.2 Study III 
Twenty-four patients participated in the study (12 men and 12 women). Patients planned for 
bowel resection (cancer or diverticular disease) were recruited from the outpatient clinic. 
Exclusion criteria before start of study were patients with metastatic disease, age >80 years, 
pre-menopausal women or previous history of abdominal surgery except for appendectomy. 
They had no history of diabetes, pulmonary, kidney, liver or ischemic heart disease. 
 
3.2.3 Study IV 
Twelve patients (3 men and 9 women) planned for gastric by-pass surgery for obesity 
participated in the study. Recruitment was made from the elective waiting list for gastric by-
pass surgery. Their mean age was 36 ±2 years and BMI was 45.3 ±1.9 kg m-2. They were on 
no medication and had no history of diabetes. 
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4 METHODS 
 
4.1 STUDY 1 
  
4.1.1 Ghelin GTPγS binding assay 
GTP gammaS is a G-protein activating analogue of guanosine triphosphate (GTP). Its 
labelled radio-ligand is used in G-protein receptor binding studies. 
  
4.1.2 Rat isolated tissues 
Sections of jejunum or stomach from adult male Sprague-Dawley rats were used in an 
organ bath for in vitro studies. Obestatin (100 nM) or vehicles were added for 
measurement of jejunal basal muscle contractility. To measure nerve-mediated 
contractions of forestomach preparations, obestatin (0.01 nM-1 µM) or ghrelin (0.1 µM) 
were stimulated with EFS. To combine the two peptides and study the interactions 
between obestatin and ghrelin on EFS-evoked contractions, obestatin (0.01 nM-1µM) 
was added 1 min before 15 min application of ghrelin. Additionally, in separate 
experiments, 3 µM of prucalopride or ghrelin (0.1 µM) were added after applying 
obestatin. Results were expressed as percentage of mean amplitude of 10 µM 
acetylcholine-induced contractions. 
 
4.1.3 Rat GI motility in vivo 
 Three bipolar steel electrodes were implanted into the muscular wall of the small 
intestine (5, 15, 25 cm from pylorus) of male Sprague-Dawley rats (n=7) and for gastric 
emptying studies an additional indwelling polyethylene catheter was placed in the 
gastric forestomach. During experiments rodents were placed in Bollman cages (Fig 6) 
and electrodes were connected to an EEG preamplifier operating a Grass Polygraph. 
The MMC cycle length, propagation velocity and duration were measured during 
fasting and fed conditions. Three sets of experiments of the effect of ghrelin or saline on 
MMC were performed: 
I A bolus of 2 ml of Isosource (1 kcal ml-1) was administered through the 
gastric catheter during 3 min. Ten minutes later, either saline or ghrelin (300, 1000 
or 3000 pmol kg-1 min-1) was administered intravenously (IV) at a rate of 5-45 µl 
min-1 until fasting motility pattern of MMC returned. 
II After a 60 min period of control, ghrelin (1000 pmol kg-1min-1) or saline 
were given (15 µl min-1) continuously over 4 hours. MMC cycles with fasting 
phase III motility pattern was measured. 
III For a period of 6 hours, saline or ghrelin (1000 pmol kg-1min-1) were 
alternatively administered for 60 min and fasting motility pattern was studied. 
 
To study the effects on fasting motility of obestatin alone or in combination with 
ghrelin, additional experiments were performed. Obestatin (1000 pmol kg-1min-1) or 
ghrelin (500 pmol kg-1min-1) were infused for 60 min. After a recovery period of two 
days the same rats that previously received the ghrelin infusion were now administered 
an infusion of obestatin (2500 pmol kg-1min-1) and 10 min later an additional infusion 
of ghrelin (500 pmol kg-1 min-1). Both infusions continued for another 60 min. 
 
 
  
 
 12  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 4.1.4 Gastric emptying of rat 
After an 18 hours fasting period, with free access to water, an infusion of obestatin 
(1000 and 30 000 pmol kg-1min-1) or saline was infused for 10 min. After the loading 
period, 0.5 ml of a radioactive solution (polyethylene glycol) or 50% of the 
polyethylene glycol (PEG) combined with an enteral feeding solution (Isosource) was 
administered for 30 s via the gastric catheter. The infusion of obestatin or saline 
continued for another 20 min. Thereafter the rats were killed, abdomen opened and the 
stomach removed after ligation of distal end of esophagus and the pylorus. The amount 
of remaining radioactive substance was calculated in a gamma counter for 60 seconds. 
Gastric emptying rate was calculated from the percentage of radioactive marker 
remaining in the stomach after 20 min compared to a standard of an equal volume of the 
radioactive marker. 
 
4.2 STUDY II 
 
4.2.1 Human tissue 
Full thickness tissues were excised from surgical specimens in the operation theatre and 
immediately placed in modified Krebs solution. Six samples were taken from colon, 
gastric antrum and duodenum from patients undergoing surgery for cancer. The tissues 
were placed in organ bath and both basal and EFS muscle contraction was performed. 
Ghrelin in increasing concentrations was applied and results expressed as percentage of 
mean values of acetylcholine. 
Fig 6. Rat in a Bollman cage (upper arrow) with electrodes connected to a 
Grass Polygraph 7B and a paper recording of the MMC (lower arrow). 
 
 
 
  
 
 13  
 
4.2.2 Study design 
The design was a randomised double-blinded cross-over study with at least 2 weeks 
between the two-study periods. The study was conducted over three days and started 
the evening before the infusion day as the subjects swallowed capsules containing 20 
radio-opaque markers. The following morning another capsule with 20 differently 
shaped markers was swallowed. Two hours later a calorie-fixed breakfast was served 
and an infusion of either saline or ghrelin (15 pmol kg-1min-1) was started. Together 
with breakfast, 1.5 g of acetaminophen and 15 ml of lactulose were ingested. During 
the day, at repeated intervals, plasma and breath samples were taken. Hunger, fullness 
and nausea were documented on a visual analogue scales (VAS) and a questionnaire 
regarding the bowel movements were filled out throughout the study period. The 
following day and 2 days after a plain X-ray of the abdomen was taken to calculate 
the number of remaining markers as well as the geometric index. 
4.2.3 Gastric emptying of humans 
The gastric emptying was assessed by the acetaminophen method [90]. The drug 
concentrations were converted to cumulative values and an absorption curve was made. 
Each individual absorption curve was inverted and transformed to a third-degree 
polynomial reflecting the gastric emptying profile. The T50 value (50% of the total 
cumulated dose emptied) was also calculated. 
 
4.2.4 Oro-caecal transit 
The breath hydrogen test was used to measure the transit time from oral ingestion of 
lactulose to arrival in the proximal part of colon. Briefly, lactulose (including lactose) is 
fermented by bacteria in the colon, where carbondioxid (CO2) and hydrogen (H2) is 
produced. The gases are absorbed by the colonic wall, transported via the veins to the 
lungs and exhaled via the breath. In our study alveolar breath samples were collected in 
bags every 10 min for 3 hours and immediately analysed by a Quintron Microlyzer. The 
oro-caecal time was defined as either an increase of hydrogen by at least 10 ppm or as 
doubling of hydrogen or methane concentrations. An early rise, or a high baseline level, 
may be a sign of small bowel bacterial overgrowth and was ruled out prior to the test. 
Patient instructions included fasting for 10 hours, no smoking or alcohol, avoidance of 
high-fiber containing meals and milk products. 
 
4.3 STUDY III  
 
4.3.1 Study design 
The design was a randomised, double-blinded study performed at a single-centre with at 
least 4 days apart. The first study day took part in an outpatient clinic and second in the 
ward 2 days after surgery. Randomisation was done by envelope draw. On both 
occasions the study began in the morning at 9 am after an overnight fast and the 
subjects received either a 3-hour infusion of 0.9% saline or ghrelin (15 pmol kg-1min-1) 
IV. Before the infusion started, an oral nutritional drink with 480 kcal was ingested 
followed by 1.5 gram of acetaminophen dissolved in water. During the infusion blood 
samples were drawn repeatedly and VAS were completed for hunger, fullness and 
nausea. A patient questionnaire for bowel movements was filled in from first study day 
until discharge. 
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4.4 STUDY IV 
 
4.4.1 Study design 
The study was performed the day before and 3 days, 2 months and 1 year after RYGB 
surgery. After an overnight fast, the subjects swallowed 1.5 g acetaminophen together with a 
200 ml liquid meal (300 kcal). Blood samples were taken before and at repeated intervals for 
180 minutes. A standard RYGB with 1 meter Roux was performed laparoscopically in each 
patient. 
 
5.0 ANALYSIS OF GLUCOSE, INSULIN AND GASTRO-
INTESTINAL PEPTIDE HORMONES 
 
Blood samples were collected in prechilled EDTA vacutainer tubes at different time-points. 
In study III a protease inhibitor cocktail together with DPP-4 inhibitor were added. Samples 
were centrifuged at 4o C for 10 min at 3000 r.p.m. 
 
5.1 RIA (radioimmunoassay) 
In study II ghrelin (total) and GLP-1 were measured with a RIA kit. In study IV leptin, 
insulin, glucagon, GIP, somatostatin and GLP-1 was measured with a RIA kit. 
5.2 Multiplex immunoassay panel (Luminex system) 
In study II GIP, insulin, PYY and leptin were analysed with a multiplex immunoassay 
panel on a Luminex reader. 
5.3 Mutarotase and glucose dehydrogenase. 
In study II and IV glucose was measured by an enzyme assay (mutarotase and glucose 
dehydrogenase) with an YSI 2300 STAT Plus. 
5.4 Fluorescence-immunoassay  
In study II acetaminophen was assessed by fluorescence-immunoassay. 
5.5 Biochemistry analyser 
In study III plasma glucose levels and acetaminophen were measured by an automatic 
chemistry analyser (Architect C8000) 
5.6 HPLC (high-performance liquid chromatography) 
In study IV acetaminophen was measured by HPLC. 
5.7 ELISA (enzyme-linked immunosorbent assay) 
In study IV ghrelin (total) was measured with an ELISA kit. 
5.8 Electrochemiluminescence detection  
In study III human acylated ghrelin was analysed utilizing electrochemiluminescence 
detection (Meso Scale Discovery). 
5.9 Metabolic hormone panel bead-based immunoassay 
In study III GLP-1, GIP, insulin, PP and PYY were analysed using a human metabolic 
hormone panel magnetic bead-based immunoassay (MAGPIX, Millipore) 
6.0 Assessment of insulin resistance with HOMA-IR 
To measure the change of insulin sensitivity in study IV the homeostatic model assessment 
of insulin resistance (HOMA-IR) was used [91]; 
 
Fasting insulin (µU/mL) x Fasting glucose (mmol/L) 
22.5 
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7.0 VISUAL ANALOGUE SCALE 
In studies II-IV, during the infusion of ghrelin or saline, the subjects were at regular intervals 
asked to estimate their feeling of hunger, fullness and nausea. A visual analogue scale (VAS) 
of 100 mm was used (appendix). The intra (0-10 min) and inter-meal (+10 min until end of 
infusion or after breakfast to before lunch in study II) changes were calculated [92]. 
 
8.0 ETHICS 
 
The regional Ethics committee of Stockholm approved the human studies I-IV including the 
collection of human tissue. Study II was also approved by the Radiation protection committee 
of the Karolinska University Hospital, Solna, Sweden. All subjects gave oral and written 
informed consent. Rat studies (study I) were approved by the animal care committee of UK 
and the Ethics Committee in northern Stockholm for the humane use of experimental animals 
in research. 
 
9.0 DATA AND STATISTICAL ANALYSIS 
  
For data acquisition and analysis of experiments involving rat tissues in vitro in study I, MP 
100 hardware and AcqKnowledge were used. For statistical analysis and graph presentations 
GraphPad Prism (La Jolla, CA, USA), with continuously updated versions being used. Data 
are shown as mean ±SEM. The statistical significance of any differences between unpaired 
data was determined using Student's t-test or Mann-Whitney U test. For matched pairs 
Wilcoxon signed rank test was used (gastric emptying data, area under the curve) for 
peptides, oro-caecal and colonic transit and VAS. AUC was calculated using the trapezoidal 
rule. P<0.05 was considered as statistically significant.  
 
10.0 RESULTS 
 
10.1 STUDY I 
10.1.1 Ghrelin GTPγS binding assay 
Ghrelin showed a concentration-dependent increase in receptor binding ability. Obestatin 
alone or in combination with ghrelin showed no agonist or antagonist activity at the human 
ghrelin receptor.  
 
10.1.2 Rat isolated tissues  
Obestatin (100 nM) had no effect on baseline contraction on jejunal muscle strips or on nerve 
induced muscle contractions (EFS) in isolated forestomach tissue. In contrast to these 
findings, ghrelin (0.1 µM) increased the EFS-evoked contractions by 40% (42.7 ±7.8%) in rat 
forestomach. Combination of ghrelin and obestatin resulted in a significant inhibition of the 
excitatory response of ghrelin. However, the response was only achieved with obestatin in the 
two lowest concentrations (0.1 nM and 1 nM, p<0.05). In similar experiment with 
prucalopride instead of ghrelin as test substance, a larger increase of EFS-evoked contractions 
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was observed. When prucalopride was added to obestatin, no reduction of the excitatory 
response was found. 
 
10.1.3 Rat GI motility in vivo 
During fasting the MMC cycle length was 15 ±0.8 min. When the nutritional solution with 
Isosource was administered, the return of fasting MMC pattern (phase III) at J2 was shortened 
by increasing concentrations of ghrelin (Table 1). The next sets of experiments of fasting rats 
infused with ghrelin (1000 pmol kg-1min-1) or saline during 4 hours shortened the MMC cycle 
length only the first hour compared to saline (p<0.05). The same results were found when 
ghrelin (1000 pmol kg-1min-1) or saline were given as alternating infusions for 6 hours.  
 
  Table 1. The effect of ghrelin on MMC (*=p<0.05).  
 
 
 
 
 
 
 
 
In the next set of experiments on fasting rats infused with ghrelin and obestatin, the control 
period of saline was 13.5 ±1.5 min. Obestatin had no effect on the MMC cycle length, 
duration of activity fronts or propagation velocity. As expected, ghrelin significantly 
shortened the MMC cycle length. Addition of ghrelin to obestatin did not significantly change 
the results from the saline infusion (Fig 7). 
 
 
                    Fig 7. The effect of obestatin and ghrelin on MMC. 
 
 
10.1.4 Gastric emptying of rat 
During saline infusion the remaining radioactive non-nutrient PEG meal was 32.2 ±2.2 % and 
combined radioactive PEG and Isosource 35.4 ±2.3 % of the initially administered meal. 
There was no significant difference in gastric emptying of nutrient or non-nutrient liquid 
solutions when the infusion of obestatin (1000 or 30 000 pmol kg-1 min-1) was given (34.1 
±2.2 % and 33.5 ±3.8; 31.3 ±2.1 and 34.8 ±3.0 %, nutrient and non-nutrient liquid, 
respectively for each dose studied). 
 
Infusion (pmol kg-1min-1) Time to phase III (min) 
saline 39.4 ±1.9 
ghrelin (300) 37.8 ±13.2 
ghrelin (1000) 33.4 ±1.9* 
ghrelin (3000) 29.5 ±0.5* 
 
 
  
 
 17  
 
10.2 STUDY II 
10.2.1 Human tissue in organ bath 
Experiments with muscle segments from human tissues did not show any contractile response 
when ghrelin was added in increasing concentrations (Fig 8). When EFS was used before and 
after application of ghrelin, gastric tissue (not duodenal or colonic) responded with an 
increase from 78 ±20 % to 125 ±30 % (of maximum response to ACh). 
 
 
Fig 8. Increasing concentrations of ghrelin added to stomach (S), duodenum (D) and colon 
(C). Acetylcholine (ACh) was used to verify tissue viability and as positive control.  
W = wash-out. 
 
10.2.2 Study subjects 
No adverse events were noticed during the study period and all subjects followed strictly the 
time schedule of study protocol with ingested markers and X-ray in similar way.  
 
10.2.3 Gastric emptying 
The gastric emptying rate was faster during ghrelin infusion compared to saline. The half 
emptying time was significantly shorter during ghrelin infusion (50.3 ±3.9) than during saline 
infusion (59.9 ±4.4 min) (p=0.002) (Fig 9). 
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10.2.4 Oro-caecal transit time 
The oro-caecal transit time was unchanged with ghrelin as compared to saline (40 ±7.8 min 
and 46 ±9.7 min, respectively). 
10.2.5 Colonic transit 
We found no differences of the remaining number of radio-opaque markers in the colon and 
no difference in distribution of defined segments of colon day 1 or day 2 (Fig 10). 
 
Fig 9. Gastric emptying rate in normal human volunteers using the 
acetaminophen method during an infusion of ghrelin (15 pmol kg-1min-1) or 
saline. 
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 Fig 10. A schematic sketch of distribution (mean ± SEM) of radio-opaque markers. 
Data from patient questionnaires revealed unchanged bowel movements by ghrelin infusion 
during all study days. 
10.2.6 Glucose homeostasis and GI peptide hormones 
The serum concentrations of ghrelin rose rapidly and reached a four-fold level with a 
maximum of 334 ±52 pmol L-1 at 120 min after the infusion of ghrelin was started. As 
expected, a decrease of endogenous ghrelin concentrations were observed after breakfast 
(Fig 11). 
 
 
Fig 11. Plasma levels of ghrelin during infusion of ghrelin or saline. Postprandial decrease of 
ghrelin after breakfast meal encircled in red. 
 
The infusion of ghrelin resulted in significantly elevated plasma glucose concentrations after 
breakfast and lunch meals compared to saline infusion (AUC0-360 2587 ±108 vs 1913 ±105 
min mmol L-1) (p<0.001). Consequently, plasma insulin was significantly higher during the 
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ghrelin infusion compared to saline (AUC0-360 50678 ±4002 vs 33588 ±4273 min pmol/L) 
(p< 0.001). 
The insulinogenic index was not significantly different (17.5 ±1.9 vs 19.7 ±1.5 saline and 
ghrelin, respectively). Plasma GLP-1 was significantly elevated during ghrelin infusion 
(AUC0-360 8717 ±588 and 6609 ±552 min pmol L-1, p=0.001). The plasma levels of GIP, 
PYY and leptin did not differ during saline or ghrelin infusions. 
10.2.7 Visual analogue scale 
Hunger ratings were higher throughout the ghrelin infusion as compared to saline. The 
inter-meal (after breakfast to before lunch) change in hunger rating was significantly higher 
during ghrelin infusion (40 ±5 vs 23 ±4) (p<0.05). Similarly, ratings of fullness were lower 
throughout the ghrelin infusion compared with saline, but the inter-meal change in fullness 
was not different (33 ±6 vs 26 ±5). Nausea ratings were low and not different between 
ghrelin and saline infusions. 
 
10.3 STUDY III 
10.3.1 Patients 
Twenty-two patients were enrolled for the study. Four patients were excluded. Two were 
incidentally administered acetaminophen for pain relief the night prior to the study and were 
not studied postoperatively. One patient showed early signs of anastomotic leakage and one 
patient could not consume the liquid meal and were therefore not studied postoperatively. 
Eleven patients remained in the saline group (7 men) and 9 patients (3 men) in the ghrelin 
group (table 4, 5). Heart rate and blood pressure remained stable during ghrelin and saline 
infusions.  
 
 
Table 4. The study group that received saline infusion. 
 
Age BMI Surgery Hospital 
stay 
Tfb OR time Blood loss 
66 24,8 sr 5 1 109 150 
78 28,1 rh 5 2 176 400 
67 24,7 rh 4 3 157 600 
79 27,5 apr + stoma 8 5 328 1100 
56 34,1 rh 3 4 105 150 
62 24,6 sr 29 5 135 150 
68 24,8 rr + stoma 6 5 233 550 
65 36,1 sr 14 3 127 300 
81 21,8 sr 9 4 222 450 
74 21,9 sr 3 3 111 75 
68 28 apr + stoma 7 3 292 300 
rh=right hemicolectomy, rr=rectal resection, lr=left hemicolectomy, sr=sigmoid resection, 
apr=abdominoperineal resection 
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Table 5. The study group that received ghrelin infusion. Time to first bowel movements 
(Tfb). Operating room (OR). 
  
Age BMI Surgery Hospital 
stay 
Tfb OR time Blood loss 
73 21 rh 3 3 138 100 
69 22,8 rr + stoma 8 2 163 200 
75 24,1 lr 4 2 180 100 
64 24,9 rr 4 1 180 100 
73 26,7 lr 3 2 180 150 
62 24,2 sr 4 2 155 100 
63 23,6 sr + stoma 3 2 157 400 
64 26,9 sr 6 1 172 300 
66 30.9 apr + stoma 25 4 138 1550 
 
 
10.3.2 Gastric emptying 
Results from analysis of plasma acetaminophen were obtained from pre- and postoperatively 
comparisons of the same individuals but also between the groups. There was no difference of 
the AUC acetaminophen during the pre- and postoperative period during the ghrelin infusion 
(p=0.57). The study subjects that received the infusion of saline had a slower gastric emptying 
rate after surgery (p=0.02). Comparisons between study groups both before and after surgery 
indicated an increased gastric emptying rate as AUC acetaminophen was significantly higher 
with ghrelin infusion compared with saline both before and after surgery (p=0.02 and 0.01, 
respectively) (Fig 12). 
 
 
  
 
 
 
Fig 12. The AUC0-180 for acetaminophen before and after surgery with saline 
(control) and before and after surgery with ghrelin (* = p<0.05). 
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10.3.3 Active ghrelin 
Analysis of active (acylated) ghrelin confirms that supraphysiological doses of ghrelin were 
administered IV. A 40-fold elevation of ghrelin was measured during ghrelin infusion 
compared to saline. There was no difference in AUC0-180 acyl ghrelin during the pre- and 
postoperative infusion of ghrelin. 
 
10.3.4 Plasma concentrations of glucose and insulin 
There was no difference in the AUC0-180 glucose between the pre- and postoperative saline 
infusion or the ghrelin infusion. However, the infusion of ghrelin led to higher AUC0-180 
glucose both before and after surgery compared to the values obtained during the saline 
infusion (p=0.0003 and p=0.003). AUC0-180 insulin was not different during saline infusion 
pre- and postoperatively (p=0.10). In contrast to these findings, AUC0-180 insulin was 
significantly higher during the preoperative ghrelin infusion compared to the postoperative 
ghrelin infusion (p=0.004). There was no significant difference between AUC0-180 insulin 
during ghrelin infusion compared to saline before and after surgery (p=0.08 and 0.17, 
respectively). 
 
10.3.5 Visual analogue scale 
The inter-meal change in hunger rating was 23.4 ±5.7 and 8.1 ±5.1 for saline infusion before 
and after surgery, respectively. The change during ghrelin infusion was 35.1 ±15.2 and 34.4 
±11.3 before and after surgery, respectively. The only significant difference was between 
saline and ghrelin infusion post-operatively (p=0.05). There was no difference in fullness or 
nausea ratings before and after surgery during saline and ghrelin infusion. 
 
10.3.6 Plasma concentrations of GLP-1, GIP, PP, PYY 
There were no differences in AUC0-180 of GIP, GLP-1, PP and PYY during saline or ghrelin 
infusion before or after surgery. The AUC0-180 of these peptides was not different between 
ghrelin and saline before and after surgery. 
 
10.4 STUDY IV 
10.4.1 Subjects 
A significant weight loss was reached at 2 months (p=0.003) and 1 year (p=0.003). 
 
10.4.2 Analysis of acetaminophen absorption (gastric and pouch emptying) 
The absorption of acetaminophen reflecting gastric or pouch emptying was significantly 
different after RYGB compared to before. The time to maximum plasma concentrations of 
acetaminophen was almost immediate after intake of liquid meal compared to pre-operative 
levels (61.9 ±5.0 min). The half emptying time of acetaminophen was also halved after 
surgery and remained constant over time (Fig 13). 
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Fig 13. Half-maximum absorption time and AUC of acetaminophen (* = p<0.05). 
 
10.4.3 Analysis of fasting glucose and insulin  
Fasting plasma glucose concentrations remained lower compared to preoperative values 
during the whole study period. Consequently, plasma insulin was significantly decreased at 2 
months and 1 year. HOMA-IR was also reduced at 2 months and normalized at 1 year (Fig 
14). 
 
Fig 14. Fasting plasma concentrations of glucose and insulin (* = p<0.05)  
  
 
10.4.4 Analysis of fasting pancreatic glucagon, enteroglucagon, GLP-1 and GIP 
Plasma concentrations of total glucagon were measured in plasma. Fasting plasma levels of 
pancreatic glucagon were unchanged at all time points. Enteroglucagon levels (result of 
subtraction of pancreatic glucagon from total glucagon) were significantly decreased only on 
day 3. Fasting GLP-1 was also unchanged. GIP was significantly decreased at day 3 and 1 
year after surgery. Plasma somatostatin was not significantly changed at different study 
points compared with before surgery. 
10.4.5 Analysis of fasting leptin and ghrelin 
Fasting levels of ghrelin were unchanged at all time-points. Leptin as expected was 
significantly reduced after 2 months and 1 year. 
 
10.4.6 Analysis of post-prandial glucose and insulin 
The whole curve was shifted to the left even though the peak of glucose occurred at 30 min 
both before and after surgery. The RYGB surgery resulted in an earlier rise and steeper 
decline of plasma glucose. Insulin followed a similar pattern with peak concentrations at 20 
min and a leftward shift of the curve. AUC0-180 for glucose and insulin were unchanged 
throughout the study period. 
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10.4.7 Analysis of post-prandial pancreatic glucagon, enteroglucagon, GLP-1 and GIP 
Plasma levels of pancreatic glucagon were elevated at 2 months but were unchanged from 
pre-operative values at 1 year. Enteroglucagon, GLP-1 and GIP showed a similar pattern with 
leftward shift of plasma concentrations after surgery and a progressive rise over time. 
Somatostatin showed a rightward shift with a peak appearing later. Pancreatic glucagon 
AUC0-180 was increased on day 3 and 2 months but not at 1 year after surgery. AUC0-180 for 
enteroglucagon and GLP-1 were significantly increased both at day 3, 2 months and 1 year. 
AUC0–180 for GIP were unchanged pre- and postoperatively. Somatostatin AUC0–180 was 
significantly decreased on day 3 only and then returned to baseline AUC at other study 
points. 
 
10.4.8 Analysis of post-prandial leptin and ghrelin 
Plasma ghrelin AUC0-180 was significantly lower on day 3 after surgery but not significantly 
different at 2 months and 1 year. Leptin AUC 0-180 min was significantly lower at 2 months 
and 1 year (Fig 15). 
 
 Fig 15. AUC0-180 minutes of ghrelin and leptin (* = p<0.05). 
 
 
10.5 Analysis of visual analogue scale 
Intake of a 200 ml liquid meal decreased the feelings of hunger on day 3, 2 months and 1 
year. Similarly, fullness increased. 
 
 
11.0   DISCUSSION 
 
Focusing on ghrelin as an important regulator of GI motility we sought to clarify its role by 
different approaches, based on endogenous secretion and exogenous administration of the 
peptide as likely to be encountered in the clinical setting of surgery. The studies encompass 
investigations of ghrelin in animals as well as human experimental models, together with 
broad-based assays of GI peptide hormones known to be of regulatory importance for GI 
motility and metabolic control. 
 
The aim of our first study included in this thesis was to further study the role of ghrelin in GI 
motility in vitro and in vivo in rodents and to investigate the ability of obestatin and ghrelin 
(alone or in combination) to affect the rat GI motility in vitro and in vivo. Thus, in part we 
tried to repeat, but also to extend the studies of Zang et al [56]; however, with little success. 
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Later studies clearly show obestatin to have no role in GI motility and questionable 
importance for body weight control [93]. 
 
The ability of ghrelin to hasten gastric emptying and stimulate MMCs in the rat and human is 
interesting in view of its metabolic consequences. Our study on ghrelin's effect on small 
bowel motility in rat confirmed previous findings, but also showed that the effect on MMC is 
diminished after an hour. A 4-hour infusion, as well as, alternating ghrelin or saline for 6 
hours in fasting rats showed the same results. One explanation may be the degradation from 
active (acylated) to des-acylated ghrelin by the DPP-4 enzyme. There might also be a 
desensitization of the GOAT enzyme to activate circulating des-acyl ghrelin. Studies with 
peripherally administered des-acyl ghrelin have been shown to inhibit the fasting motility of 
the stomach [24], probably by crossing the BBB and acting centrally in the brain [25].  
 
Our study showed very little effect of obestatin on GI motility and no interaction with ghrelin. 
The first study of obestatin by Zang et al proposed that the peptide decreased the gastric 
emptying rate and prevented body weight gain [56]. Furthermore, the author claimed that it 
decreased the contractility of jejunal strips in vitro and counteracted the effect of ghrelin. Our 
results could not confirm any significant effect of obestatin (from two different suppliers) on 
gastric emptying in a nutrient or non-nutrient setting nor the MMC pattern. Our only positive 
data of obestatin was on experiments with rat isolated gastric tissue where obestatin in the 
lowest dose range inhibited the excitatory response of ghrelin. In a follow-up study published 
in 2008 [94], the same author explained that the original peptide preparation was 
contaminated and some experiments could not be reproduced. However, the purified obestatin 
still showed binding properties to the GPR39, a receptor that belongs to the same family as 
the ghrelin receptor.  
 
One interesting hypothesis by Depoortere and al [61] is that obestatin may be inhibited by 
endogenously secreted ghrelin. The effect of obestatin on gastric emptying and food intake 
was studied in fasted ghrelin knockout mice and wild types. They found no effect in either 
group of mice and concluded that even though endogenous ghrelin is abolished, no effect of 
obestatin is found on GI motility. 
 
In summary, we could only show a modest effect of obestatin on gastric muscle contractility 
in vitro and no interaction with ghrelin. The results from our ghrelin studies are in line with 
those of others but also show a reduced effect after an hour. 
 
Even though obestatin is derived from the same precursor gene as ghrelin its role might be of 
a different nature than that of ghrelin [93]: inducing cell proliferation of ovarian cells [95] and 
promoting survival of β-cells of the pancreas [96], inhibition of water drinking [63] and 
improving memory [62]. 
 
Ghrelin receptors are present throughout the GI tract including colon and rectum [17]. Studies 
in rat show that ghrelin stimulates motility in the small intestine [33, 34] and colon [97]. The 
effect of ghrelin on upper GI motility in humans was first studied in 2006 [98]. Infusion of 
ghrelin induced a premature gastric phase of the MMC in healthy volunteers and accelerated 
gastric emptying in patients with gastroparesis due to diabetes or surgical vagotomy [35, 36]. 
Supraphysiological doses of ghrelin or ghrelin agonists (ulimorelin) administered to healthy 
volunteers resulted in increased appetite and decreased satiety with few side effects [99]. A 
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correlation with elevated plasma glucose levels and free fatty acids was found [99]. In spite of 
these findings few studies have examined the effect of ghrelin on small bowel and colonic 
transit in human. 
 
In our second study a 6 hours IV infusion of saline or ghrelin was given to healthy volunteers 
in order to measure gastric emptying, oro-caecal and colonic transit. Additionally, in vitro 
studies of human tissue from the GI tract were performed. As expected, our results 
demonstrated an increased gastric emptying rate and elevated hunger feelings during the 
ghrelin infusion, suggesting that the peptide was biologically active. We found no difference 
in oro-caecal or colonic transit time between the study groups and the number of bowel 
movements were unchanged. One of the recognised incretins, GLP-1, was significantly 
elevated but not GIP, PYY or leptin. With the increased rate of gastric emptying seen during 
an infusion of ghrelin there is a faster emptying of nutrients into the duodenum and 
subsequently a faster stimulation of the GLP-1 producing L-cells. The fact that PYY (co-
localized in the same L-cells) remained unchanged was surprising, but may be due to the 
composition of the meal used. 
 
Postprandially the plasma concentrations of glucose and insulin were significantly elevated as 
was the insulinogenic index calculated from the total period of 360 min. There was also a 
significant correlation between the release of insulin and glucose uptake. The relationship 
between release of GLP-1 and uptake of glucose was only borderline significant. The findings 
of elevated glucose concentrations in plasma are in line with other studies [53, 100, 101]. 
More recently, studies have suggested that exogenously given ghrelin directly stimulates the 
liver to increase glucose output by both enhanced glycogenolysis and gluconeogenesis [102]. 
The elevated glucose and insulin levels may reflect an impaired insulin sensitivity with 
decreased peripheral uptake of glucose. Ghrelin has been found to have no effect [99, 103], 
stimulatory [104] or inhibitory effect [100] on insulin secretion. During fed conditions the 
majority of studies show that ghrelin delays glucose stimulated insulin secretion by the 
pancreas [52, 105, 106]. In our study the elevated GLP-1 levels during the ghrelin infusion 
may contribute to the increased plasma concentrations of insulin and is likely due to the rapid 
entry on nutrients into the small intestine after the increased rate of gastric emptying. 
 
Our results in this study do not support the hypothesis that an intravenous infusion of ghrelin 
stimulates small bowel and colon motility in healthy humans. The effect of ghrelin seems to 
be limited to the stomach and duodenum. Our study was conducted under fed conditions but 
are in line with a study by Tack et al where IV administration of ghrelin to fasted healthy 
volunteers induced a premature phase III fasted motor activity and increased the gastric tone 
[98]. Our findings are supported by our in vitro studies of tissues from different parts of the 
GI tract where only gastric tissue responded with enhanced contractile response to electrical 
field stimulation. Previous studies have confirmed that gastric motility is dependent of an 
intact vagus nerve [28, 107], although the local enteric nerve system may in some cases 
compensate for the lack of vagal input [34].  
 
In our study the inability of ghrelin to stimulate colonic motility may be due to a poor 
penetration of the central nervous system. It is well known that the distal colon and rectum are 
innervated by the autonomic nerve system and that the defecation control centre is located in 
the lumbo-sacral spinal cord. Studies with synthetic ghrelin receptor agonists applied directly 
into the region cause propulsive contractions in rat [97], as well as, contractile activity of the 
 
 
  
 
 27  
bladder [108]. Peripheral administration of ghrelin receptor agonists, able to cross the BBB, 
are more likely to stimulate the colon motility [109]. Recent studies have confirmed the 
presence of ghrelin receptors on preganglionic neurons in the spinal cord of mice [110] and 
that the ghrelin agonist, capromorelin, even stimulates defecation in rats after spinal cord 
injury [108]. 
 
One critique of our study may be the methods used for assessing the gastric emptying and 
transit time of small bowel and colon. The "golden standard" to assess gastric emptying is 
scintigraphy. The advantage of this test is that both solid and liquid meal may be studied and 
sometimes show the distribution within the stomach. The disadvantage is the high cost, the 
requirement of radioactive substances and a gamma camera. In our study the acetaminophen 
(paracetamol) tracer technique was used. This method is commonly used and correlates well 
with the scintigraphic technique, but is less expensive and does not require handling of 
radioactive material [90]. The lactulose breath test is the most widely used technique to assess 
oro-caecal transit in human. False positive results may be obtained if the small bowel contains 
bacteria. This was ruled out as the baseline level was low and no early rise was seen. Another 
disadvantage of the method is the lack of reference time in healthy individuals and "normal" 
oro-caecal time may vary between 1-6 hours depending of the food or fluid contents. The 
strength in this study was a cross-over study with the same individual studied twice in a 
similar way. Finally, the colon transit method in our study was modified from the commonly 
used method for assessing slow transit. To ensure that markers were located in the intestine 
and not the stomach, different markers were administered the evening prior to the study and 
the same morning. As the mean oro-caecal transit time in our study was 40 ±7.8 min in the 
ghrelin group, it would have been preferable to perform the x-rays before and directly after 
the infusion as well. However, the number of abdominal X-rays that we could perform were 
limited by the Radiation Protection Committee.  
 
In summary, this study shows that supraphysiological doses of ghrelin fasten the gastric 
emptying but do not affect the oro-caecal or colon transit in healthy human volunteers. The 6-
hour infusion of ghrelin resulted in postprandially elevated levels of glucose, insulin and 
GLP-1, most likely due to the enhanced gastric emptying rate. 
 
The interesting finding that ghrelin stimulates gastric emptying in animal models of POI [30, 
111, 112] encouraged us to further investigate the possibility of obtaining the same results in 
patients undergoing major abdominal surgery. POI is a common problem in surgery and may 
lead to symptoms as nausea, abdominal bloating and pain. Even though the ERAS concept 
(enhanced recovery after surgery) improves the clinical outcome, prolonged hospital stay due 
to POI is still common. We therefore performed a randomised double-blinded study where 
patients undergoing surgery for cancer or diverticulitis received a 3-hour infusion of ghrelin 
or saline before surgery and on post-operative day 2.  
 
We found that an infusion of ghrelin two days after open bowel resection increases the gastric 
emptying rate and shortens the time to first defecation. The GLP-1 and GIP responses, as well 
as, PP and PYY were unchanged before and after the surgery in both study groups. In 
contrast, we found a significant pre-operative increase of insulin before surgery in the ghrelin 
group. The total amount of absorbed acetaminophen (measured as AUC) during saline 
infusion was significantly lower after surgery compared to before. The ghrelin infusion 
normalized the delayed emptying postoperatively. These results are in agreement with the 
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well-known fact that abdominal surgery causes paralysis of the upper GI tract. The findings 
that a ghrelin agonist enhance the gastric emptying rate after colectomy has previous been 
reported by Popescu et al [113]. However, the primary endpoint in their study was time to 
first bowel movement and secondary endpoint return of GI function. Patients receiving the 
ghrelin agonist experienced less nausea and vomiting which was interpreted as accelerated 
recovery of the upper GI tract. We did not observe any difference in nausea, hunger or 
fullness during the ghrelin infusion in our study. In this study observations on day 2, were 
chosen due to various reasons. Intake of oral fluids should be tolerated and pain management 
with epidural catheter established (avoidance of opioids). Additionally, confounding factors 
related to the anaesthesia should be excluded as well as normalizing of stress-induced 
elevation of endogenous levels of ghrelin [114]. 
 
The finding that a 3-hour infusion of ghrelin shortens time to first defecation indicates that 
ghrelin modulates the total GI transit in patients undergoing bowel surgery. The patients were 
allowed intake of solid food already on day 1 after surgery. Therefore, nutrients had been 
introduced into the intestine before the infusion of ghrelin enabling bowel movements. As 
discussed above, the same results in human have been obtained with administration of the 
ghrelin agonist [113]. Studies in rat have shown that intracerebral administration of ghrelin 
decreased the colonic transit time up to 43% [115]. The same results with stimulated 
propulsive activity in colon were seen with injected ghrelin into the spinal cord [116]. It 
seems unlikely that ghrelin in our study was able to pass the BBB and stimulate the central 
nervous system. The most likely explanation for our finding is that the hastened gastric 
emptying postoperatively facilitates bowel movements via the gastro-colic reflex. In contrast 
to our second study we found no elevation of GLP-1 or other GI peptides that influence 
motility despite the stimulated gastric emptying. This might be due to the different 
composition of the meal and the post-operative metabolic condition. An unchanged GLP-1 
response to colon surgery has also been shown in a study by Palnaes Hansen [117] and Nauck 
et al [118]. 
 
In line with our second study, the infusion of ghrelin increased the plasma concentrations of 
glucose. The mechanism behind the significant increase of insulin before surgery is not clear. 
In normal conditions ghrelin has been shown to inhibit insulin secretion. After surgery, in 
spite of the ERAS concept, patients show a decreased insulin sensitivity [119], which could 
result in elevated levels of insulin. We suggest that the role of ghrelin in glucose homeostasis 
after intestinal surgery is further studied. Our study has some weaknesses. The number of 
study subjects is small and the colorectal surgical procedures vary between the groups. There 
was no significant difference in the time it took to complete the surgery or blood loss, but 
different parts of colon and distal ileum were resected. Three patients in each study group 
received a stoma (one ileostomy and two sigmoidal stomas, respectively) which could also 
affect the results. Furthermore not all patients were studied both before and after surgery due 
to complications of the surgery and mistaken administration of acetaminophen on the study 
day. 
 
In summary, this study shows that a 3-hour infusion of ghrelin can increase the rate of gastric 
emptying in patients with POI. We also found that time to first defecation was shorter with 
little effect on GI peptides. 
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To investigate the role of endogenous ghrelin, studies in rodents have been done with 
knockout mice and with receptor antagonists injected peripherally or intracerebrally. In 
humans no studies of ghrelin antagonists have been performed. After RYGB surgery for 
obesity it has been reported that plasma concentrations of ghrelin were both decreased [49] 
and increased [120]. Thus, it is possible that effects of endogenous ghrelin could be studied 
after RYGB surgery. In contrast, other GI peptides such as GLP-1 have been shown to be 
elevated.  
 
In our fourth study, we investigated alterations in ghrelin and other GI peptides, as well as, 
glucose responses early after RYGB surgery for obesity. Further the rate of gastric (and 
pouch) emptying was studied. Our hypothesis to use RYGB as model to study endogenous 
ghrelin was not proven correct as plasma concentrations of both fasting and postprandial 
ghrelin were unchanged with the exception of on day 3. Changes in plasma concentrations of 
ghrelin are unlikely to contribute to the improved metabolic control seen after RYGB surgery. 
There have been conflicting reports with regard to alterations of ghrelin after RYGB as noted 
above [121]. This has been attributed to different surgical techniques and to which extent the 
vagus nerve is affected by the surgery. Fasting GLP-1 levels were unchanged as well, but 
increased postprandially during the year. Fasting levels of GIP were significantly decreased 
on day 3 and 1 year after surgery but AUCs 0-180 were unchanged before and after surgery. 
 
In line with previous studies we found gradually lower values of fasting blood sugar and 
insulin levels during the first year. This was also confirmed with the HOMA test where the 
index decreased from over 6 to normal values below 2.8. The mechanism behind the early 
amelioration of the glucose homeostasis (day 3) is not clear but may be explained by energy 
restriction and increased postprandial levels of GLP-1. The hunger feelings, assessed with the 
VAS scale, were significantly decreased already day 3 as well as feelings of fullness were 
high, which also may be attributed to the elevated postprandial GLP-1 levels. Fasting insulin 
improved, reflecting the weight loss and improved insulin sensitivity [122].  
 
The rapid rise of glucose (and incretin hormones) is likely due to the rapid entry of nutrients 
into the small intestine after RYGB. We found a rapid pouch emptying after the surgery. 
Again, this was not due to alterations in ghrelin levels. 
 
In summary, our study of RYGB surgery shows a rapid emptying of the upper pouch. This 
results in increased levels of GLP-1 after meal, which may contribute to the improvement in 
glucose homeostasis seen early after the procedure. Ghrelin does not contribute to this, as 
plasma concentrations of ghrelin were essentially unchanged. 
 
In conclusion, this thesis shows that exogenously administered ghrelin increases the rate of 
gastric emptying in humans, both in healthy volunteers and after major abdominal surgery. 
The sister hormone obestatin seems to have little effect on GI motility. In our hands plasma 
concentrations of ghrelin are unchanged after RYGB for obesity, yet the rapid entry of 
nutrients into the small intestine results in increased plasma concentrations of glucose and 
GLP-1. This highlights the importance of the stomach in regulating glucose metabolism. A 
rapid entry of nutrients into the small intestine, regardless if it is due to a faster gastric 
emptying after the administration of ghrelin or bypass of the stomach in bariatric surgery, 
results in elevated plasma glucose and GLP-1. Normally the pylorus regulates the amount of 
nutrients that enter the duodenum. In the setting of our studies, the increased rate of gastric 
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(pouch) emptying after ghrelin infusion or RYGB, GLP-1 seems to be a central player that 
tries to counteract the rapid entry of nutrients into the intestine by slowing gastric emptying 
and increasing plasma insulin to balance glucose metabolism.    
 
It is possible that the physiological role of ghrelin is to prepare the GI tract for a meal and 
initiate gastric emptying, which is then counteracted by the release of incretins, which serve to 
inhibit gastric emptying and propulsion through the small bowel, as well as promote insulin 
release in order to balance a rapid nutrient uptake. It is important to realise that ghrelin acts in 
concert with a range of other GI peptides that are released separately and act differently to 
achieve metabolic control. 
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12.0 CONCLUSIONS 
 
 
¥ Obestatin does not seem to play a role in the modulation of GI gastric motility.  
 
¥ In healthy humans effect of ghrelin on GI motility is limited to the stomach and does 
not affect small bowel or colonic motility. 
 
¥ After open colo-rectal surgery ghrelin accelerates the rate of gastric emptying and 
time to first bowel movement. 
 
¥ Plasma concentrations of ghrelin are unchanged after RYGB which makes it unlikely 
that ghrelin contributes to the metabolic improvements seen after the surgery. 
 
¥ The rate of pouch emptying after RYGB is very rapid which likely contributes to the 
rapid rise of glucose, insulin and GI peptides seen after the surgery. 
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13.0 POPULÄRVETENSKAPLIG SAMMANSTÄLLNING 
 
Idag finns ett 30-tal kända peptider eller hormoner i mag-tarmkanalen som reglerar födointag, 
aptit, energi och sockeromsättning. Dessa peptider signalerar till olika centra i hjärnan. 
Peptiderna ghrelin och obestatin, som upptäcktes 1999 respektive 2005, härrör från samma 
ursprung men stimulerar olika receptorer. Ghrelinreceptorn finns i ett stort antal vävnader 
såsom mag-tarmkanalen, bukspottskörteln, njurar, fettvävnad, skelettmuskel och hjärna. Det 
finns två huvudsakliga molekylära former av ghrelin, acyl och des-acyl ghrelin med motsatta 
effekter på en rad funktioner i mag-tarmkanalen. Mag-tarmkanalens motorik styrs förutom av 
peptidhormoner även av det lokala nervsystemet i tarmen och nerver från ryggmärg och 
hjärna. Peptidhormonerna kan verka lokalt i tarmen, transporteras med blodet till hjärnan eller 
produceras direkt i hjärnvävnaden. Ghrelin påverkar en rad olika funktioner och styr hunger 
och måltidsreglering, sockeromsättning och fettförbränning. Obestatins roll i samspelet med 
ghrelin är oklar. 
Syftet med de studier som presenteras i denna avhandling var att undersöka hur ghrelin 
påverkar mag-tarmkanalens motorik samt ämnesomsättning hos råtta och människa.  
I studie 1 studerade vi förmågan hos obestatin och ghrelin (enskilt eller i kombination) att 
påverka enskilda muskelfibrers kontraktionsförmåga samt råttans tarmrörelsemönster och 
magsäckstömning. Vi fann att obestatin inte stimulerar motoriken och endast påverkar 
ghrelinet svagt. Ghrelin ger däremot en ökad magsäckstömning och stimulerar fastemotorik 
med hungersugningar. 
I studie nr 2 erhöll friska försökspersoner vid två tillfällen ghrelin eller saltlösning under 6 
timmar i följd för att jämföra effekten på magsäckstömning samt rörelsemönster i tunntarm 
och grovtarm. Frisättningen av flera mag-tarmhormoner och glukosomsättningen undersöktes. 
Vi fann en ökad magsäckstömning men ingen påverkan på passagetid i tunntarm eller 
grovtarm. Glukos- och insulinnivåer samt peptiden GLP-1 steg efter ghrelin. 
I studie 3 deltog patienter som genomgick kolo-rektal kirurgi på grund av tarmcancer eller 
tarmfickor. Preoperativt och två dagar postoperativt gavs ghrelin eller saltlösning under 3 
timmar. Magsäckstömning samt tid till första tarmtömning mättes liksom förändringar av 
tarmhormoner i blodet. Ghrelin gav snabbare magsäckstömning och kortare tid till första 
tarmtömning. Vi fann även förhöjda värden av insulin pga snabb magsäckstömning. 
Det primära syftet med studie 4 var att belysa de tidiga hormonella följderna av 
överviktskirurgi med gastric bypass kirurgi (RYGB). Kroppsegna nivåer av ghrelin och 
insulin samt peptiderna GIP och GLP-1 mättes och sockeromsättning studerades. Vi fann 
dubblerad hastighet av magsäckstömningen och förbättrad sockerbalans. Nivåerna av GLP-1 
var samtidigt förhöjda. 
Sammantaget visar arbetena att ghrelin har en kraftigt stimulerande effekt på hunger och 
magsäckens motorik och ger förkortad postoperativ hämning av tarmmotoriken. Detta ger 
sekundära effekter på ämnesomsättning och metabol kontroll genom att frisättningen av flera 
peptidhormoner från mag-tarmkanalen stimuleras. Överviktskirurgi med RYGB som också 
ger en mycket snabb tömning av näring till tarmen ger likartad hormonfrisättning, ff a av 
GLP-1, vilket ger mättnad och förbättrad metabol kontroll. Vi fann däremot inte att obestatin, 
föreslagen som motverkande till ghrelin, hade några effekter på mag-tarmkanalens motorik. 
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16.0 APPENDIX 
 
Study II 
 
Questionnaire of bowel habits 
 
 
 
 
 
 
     
DAG 0 (dagen innan ditt första besök) 
 
Besvara följande frågor VARJE GÅNG du har tarmrörelser 
 
Tid på dagen:              _ _:_ _        _ _:_ _      _ _:_ _        _ _:_ _      _ _:_ _          
  
1. Hade du gasavgång?           Ja   Nej         Ja   Nej         Ja   Nej          Ja   Nej            Ja   Nej 
  
2. Hade du avföring?              Ja   Nej         Ja   Nej         Ja   Nej          Ja   Nej            Ja   Nej 
 
3. Kände du att du                  Ja   Nej         Ja   Nej         Ja   Nej           Ja   Nej            Ja   Nej 
kunde tömma tarmen 
fullständigt?   
 
4.Var buken uppblåst  Ja   Nej 
eller utspänd? 
 
5. Kände du smärtor 
eller obehag i buken?  Ja   Nej 
 
 
 
Kommentar:………………………………………………………………………… 
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Study II  
 
Study protocol DAY 1 
 
 
Date of visit: Arrival time: :
D D M M M Y Y Y Y
DATE
 
Has the subject taken the second Sitzmarks capsule?
Yes Time: :
No please specify:
SITZMARKS CAPSULE
 
X-ray performed in the morning?
Yes Time: :
No please specify:
X-RAY
 
FASTING PLASMA SAMPLE AND EXHALED HYDROGEN
Fasting plasma sample taken?
Yes Time: :
No please specify:
 
Has the infusion been given?
Yes start: : stop: :
No please specify:
GHRELIN/SALINE INFUSION
 
Rejected breakfast: grams. Breakfast time: :
ENERGY-FIXED BREAKFAST (450 kcal, ________ grams)
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Study protocol DAY 1 
 
 
 
Has the following substances been ingested during breakfast?
1.5 g of paracetamol (Alvedon)
Yes
No please specify:
15 ml of lactulose
Yes
No please specify:
SUBSTANCE INTAKE
 
 
Rejected lunch: grams. Lunch time: :
ENERGY-FIXED LUNCH (600 kcal, _________ grams)
 
Minutes: Actual time: Signature: Hours: Actual time: Signature:
15 : 4 :
30 : 5 :
45 : 6 :
60 :
90 :
120 :
180 :
PLASMA SAMPLING
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Study protocol DAY 1 
 
 
 
Minutes: Actual time: Measurement: Minutes: Actual time: Measurement:
10 : ppm 100 : ppm
20 : ppm 110 : ppm
30 : ppm 120 : ppm
40 : ppm 130 : ppm
50 : ppm 140 : ppm
60 : ppm 150 : ppm
70 : ppm 160 : ppm
80 : ppm 170 : ppm
90 : ppm 180 : ppm
MEASUREMENTS OF EXHALED HYDROGEN
 
Time: Actual time: Hunger Fullness Nausea Signature
08:45 :
infusion
09:15 :
10:00 :
11:00 :
12:00 :
:
:
:
:
VISUAL ANALOG SCALE (VAS)
 
Investigator's signature: Date:
D D M M M Y Y Y Y
I confirm that all data captured at this visit are correct and completed to the best of my knowledge
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DAY 2 
 
Date of visit: Arrival time: :
D D M M M Y Y Y Y
DATE
 
X-ray of abdomen performed?
Yes Time: :
No please specify:
X-RAY
 
Investigator's signature: Date:
D D M M M Y Y Y Y
I confirm that all data captured at this visit are correct and completed to the best of my knowledge
 
 
DAY 3 
 
Date of visit: Arrival time: :
D D M M M Y Y Y Y
DATE
 
X-ray of abdomen performed?
Yes Time: :
No please specify:
X-RAY
 
Has the subject completed the bowel habits questionnaire?
Yes
No please specify:
BOWEL HABITS QUESTIONNAIRE
 
Investigator's signature: Date:
D D M M M Y Y Y Y
I confirm that all data captured at this visit are correct and completed to the best of my knowledge
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Visual analogue scale  
 
 
 
Fyll i detta formulär klockan  
Markera med ett streck på varje linje hur Du upplever hunger, mättnad och så vidare just 
nu! 
 
 
 
 
1                      Hur hungrig känner Du Dig just nu? 
 
Inte alls       ________________________________________    Mycket, mycket 
hungrig                                                         hungrig 
 
 
 
 
 
 
 
2       Hur mätt är Du just nu? 
 
Inte alls        ________________________________________   Mycket, mycket 
mätt                               mätt    
 
 
 
 
 
 
                Hur mycket illamående upplever Du just nu? 
 
 
  Inget illamående     ________________________________________  Maximalt 
  alls                           illamående 
 
 
 
 
 Namn _________________________________ 
  
 Datum _______________ 
 
 
 
 

